CX Institutional Cuts Stock Position in AbbVie Inc. $ABBV

CX Institutional cut its holdings in AbbVie Inc. (NYSE:ABBV) by 45.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 42,843 shares of the company’s stock after selling 35,443 shares during the quarter. CX Institutional’s holdings in AbbVie were worth $11,207,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. ACT Advisors LLC. boosted its holdings in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after buying an additional 41 shares during the period. Willner & Heller LLC raised its holdings in shares of AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after acquiring an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC raised its holdings in shares of AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after acquiring an additional 43 shares during the period. Fielder Capital Group LLC lifted its position in AbbVie by 1.7% in the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after acquiring an additional 43 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC boosted its stake in AbbVie by 0.4% in the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock worth $2,996,000 after purchasing an additional 43 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

NYSE:ABBV traded up $3.34 on Friday, hitting $263.27. 5,562,834 shares of the company’s stock were exchanged, compared to its average volume of 6,439,403. The firm has a 50-day moving average price of $257.79 and a 200-day moving average price of $234.39. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $269.39. The company has a market cap of $465.14 billion, a P/E ratio of 74.37, a price-to-earnings-growth ratio of 1.19 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s payout ratio is 195.48%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA approved AbbVie’s new Parkinson’s disease pill, Juvmo, with a commercial launch targeted for October 2026. The product expands AbbVie’s neuroscience portfolio and could provide another source of growth beyond its immunology franchise. FDA approves AbbVie’s Juvmo for Parkinson’s Disease
• Positive Sentiment: Analysts’ consensus price target was reportedly raised 10.06% to MX$5,190.34, reinforcing bullish expectations. Separately, one analysis estimated that ABBV could be 41% undervalued following the Juvmo approval, although valuation models are inherently subjective. AbbVie consensus price target increased
• Positive Sentiment: New long-term data showed AbbVie’s RINVOQ continued to improve facial and total-body repigmentation in non-segmental vitiligo patients through week 76. The findings may strengthen RINVOQ’s commercial opportunity, though safety, reimbursement and competitive considerations remain important. AbbVie presents long-term RINVOQ data
• Neutral Sentiment: AbbVie will report third-quarter 2026 results before the market opens on October 30. The event gives investors a near-term catalyst to assess Skyrizi and Rinvoq growth, the post-Humira transition and management’s outlook. AbbVie third-quarter 2026 earnings conference call
• Neutral Sentiment: An update on an ongoing Greek clinical study is evaluating venetoclax in acute myeloid leukemia. The study remains an incremental pipeline development rather than a definitive efficacy or regulatory catalyst. AbbVie’s Venetoclax AML study update
• Negative Sentiment: AbbVie agreed to participate in a U.S. government pilot testing a new prescription-drug rebate system. While participation could improve relations with policymakers and potentially expand access, changes to rebates and pricing may create uncertainty around net drug prices and margins. AbbVie joins U.S. government pilot to test drug discount rebates
• Negative Sentiment: Despite strong recent performance, investors continue to weigh AbbVie’s elevated valuation, Humira revenue erosion and competition affecting its growth outlook. These risks could limit further upside even as newer products gain traction.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ABBV shares. Morgan Stanley reiterated an “overweight” rating and set a $296.00 target price (up from $278.00) on shares of AbbVie in a report on Monday, August 3rd. JPMorgan Chase & Co. boosted their price target on AbbVie from $280.00 to $285.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Piper Sandler increased their price objective on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. UBS Group lifted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Finally, Rothschild & Co Redburn boosted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $272.66.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.